BioSpace News Archive

Dermal curettes have shown a promising potential in wide range of dermatologic surgeries, notably in cartilage sculpting tool.

Gas blending is the procedure of precise mixing of different gases for a medical or non-medical purpose in a controlled environment.

During the period July 15, 2021 until July 16, 2021, Vitrolife AB has repurchased a total of 52,568 shares as part of the buyback program introduced by the Board of Directors to secure the obligations of Vitrolife relating to the long-term incentive program LTIP2021.

Pfizer Inc. announced that Christopher Stevo has joined the company as Senior Vice President and Chief Investor Relations Officer, reporting to Chief Corporate Affairs Officer Sally Susman.

Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, announced the appointment of Ajay Rai, M.B.A., as Senior Vice President, Head of Business Development.

Passage Bio, Inc., a clinical-stage genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system disorders, announced three key leadership appointments.

Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., announced the presentation of 14 scientific posters involving the company’s ophthalmic surgical technologies at the American Society of Cataract and Refractive Surgery annual meeting, which will take place from July 23-27, 2021, in Las Vegas.

Oblato, Inc. announced that it has received an agreement from the FDA for its plan to submit an intermediate size expanded access protocol for use of OKN-007 in patients with high-grade gliomas.

Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients battling cancer, announced that it has converted all of the $28.0 million aggregate principal of the Company’s 2020 5.00% Convertible Senior Notes due 2048 in exchange for approximately 8.6 million shares of the Company’s common stock, based on the Company’s existing Mandatory Conversion right.

Eyenovia, Inc., a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print therapeutics, announced that Eyenovia will be featured at the Company Showcase on July 22 at the Eyecelerator@ASCRS and will participate in a panel discussion, entitled, “Presbyopia: Everybody gets it..